Abiomed jumps on fiscal Q3 prelims, raised outlook | Wall Street Beat

Abiomed (NSDQ:ABMD) shares got a jump today from its preliminary fiscal third-quarter numbers and an improved outlook for the rest of its fiscal year. The Danvers, Mass.-based heart pump maker said it expects to post fiscal Q3 sales of roughly $200.6 million, representing a 30.3% increase over its fiscal Q3 top line. Abiomed also raised its revenues guidance for fiscal 2019, saying it now expects full-year sales of about $780 million, up from $765 million to $770 million previously. The news sent ABMD shares, which closed up 3.7% at $313.44 apiece Jan. 4, up some 2.1% to $320 even today in pre-market trading. The company said it plans to issue its full fiscal Q3 results Jan. 31. NuVasive’s Q4, annual prelims deliver a blow NuVasive Inc. (NSDQ:NUVA) said today that it expects to post fourth-quarter sales of approximately $288 million and full-year revenues of roughly $1.10 billion. “In the fourth quarter and full year 2018, we continued to grow above market, driven by new product introductions and strong performances in key global geographies,” CEO Christopher Barry said in prepared remarks. “We are encouraged by our mid-single digit growth in a stable U.S. spine market, while experiencing some temporal surgeon case volume disruptions that impacted the fourth quarter results, along with a delay in timing of capital equipment orders. “In 2018, NuVasive launched more than a dozen new technologies and initiated several strategic partnerships—all d...
Source: Mass Device - Category: Medical Devices Authors: Tags: Featured MassDevice Earnings Roundup Wall Street Beat Abiomed Cardiovascular Systems Inc. CAS Medical Systems Inc. Nuvasive wrightmedical Source Type: news